Development of a TRK-Targeting Degrader for Cancer & Pain Indications

By | 2 February 2026
  • Discovering a potent and selective pan-TRK degrader
  • Presenting preclinical validation of the TRK degrader in cancer models
  • Discussing preclinical validation of the TRK degrader in pain models